Hedge Funds Are Buying KalVista Pharmaceuticals, Inc. (KALV)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Kalvista Pharmaceuticals Inc. (KALV)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 1,533,559 | $22,605 | 1.55% | |
| 2. | Birchview Capital Matthew Strobeck | 40,000 | $590 | 0.42% | |
| 3. | Ikarian Capital Neil Shahrestani | 39,730 | $586 | +9% | 0.07% |
| 4. | Renaissance Technologies Jim Simons | 16,800 | $248 | -26% | 0% |
| 5. | Frazier Healthcare Partners Alan Frazier | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.34 | 47,431 | Director | 1,138,179 | 2020-10-30 | Filing | |
| $17.17 | 68,255 | Director | 1,090,748 | 2020-10-30 | Filing | |
| $11.87 | 7,962 | Director | 10,000 | 2019-09-27 | Filing | |
| $11.90 | 2,038 | Director | 2,038 | 2019-09-26 | Filing | |
| $17.13 | 5,137 | Director | 124,566 | 2019-07-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.07 | 10,000 | Officer, Director | 114,670 | 2022-03-09 | Filing | |
| $18.07 | 6,000 | Officer | 2,234 | 2021-11-01 | Filing | |
| $18.07 | 5,000 | Officer | 32,969 | 2021-11-01 | Filing | |
| $17.18 | 10,000 | Officer, Director | 124,670 | 2021-10-01 | Filing | |
| $20.52 | 5,000 | Officer | 37,969 | 2021-08-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 1,544,027 | $22,757 | 0% | |
| 2. | 1,239,731 | $18,273 | 0% | |
| 3. | 1,166,652 | $17,196 | 0% | |
| 4. | 825,350 | $12,166 | 0% | |
| 5. | 484,103 | $7,136 | 0% |
News See All
Hedge Funds Are Cashing Out Of KalVista Pharmaceuticals, Inc. (KALV)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch's Stonepine Capital.
Hedge Funds Are Crazy About KalVista Pharmaceuticals, Inc. (KALV)
In this article we will take a look at whether hedge funds think KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a good investment right now.
Is KALV A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Is KalVista Pharmaceuticals, Inc. (KALV) Stock A Buy?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Were Hedge Funds Right About Piling Into KalVista Pharmaceuticals, Inc. (KALV)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Funds Are Buying KalVista Pharmaceuticals, Inc. (KALV)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Here is What Hedge Funds Think About KalVista Pharmaceuticals, Inc. (KALV)
We can judge whether KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
Is KalVista Pharmaceuticals, Inc. (KALV) A Good Stock To Buy?
Is KalVista Pharmaceuticals, Inc.
Billionaire Hedge Funds
